Clinical trial NCT06115642: A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced/Metastatic Solid Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumor
Lead sponsor: Shanghai Henlius Biotech
Sponsor class: INDUSTRY
First posted: 2023-11-03
Enrollment: 174
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX43.

Detailed description: This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX43 with escalated doses in the treatment of patients with advanced/metastatic solid tumors.

In the phase Ia of this study, a 3 + 3 dose escalation method will be adopted, and the patients will be administered with HLX43 at different doses via intravenous infusion. The DLT observation period lasts for 3 weeks after the first administration of HLX43.

In phase Ib of this study. The Safety Review Committee will recommend dose groups for expansion based on the safety, efficacy and PK data of the dose escalation phase.

Eligibility criteria: Inclusion Criteria:

1. Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the ICF; voluntarily participate in the study; be able to complete the study as per protocol requirements;
2. ≥ 18 years and ≤ 75 years at the time of signing the ICF, male or female;
3. Patients with histologically or cytologically confirmed advanced/metastatic malignant solid tumors, who are refractory to or intolerable with standard treatment, or for which no standard treatment is available;
4. At least one measurable lesion as per RECIST 1.1 within 4 weeks prior to the first administration;
5. An ECOG performance status score of 0-1 within 7 days prior to the first administration;
6. Life expectancy \> 3 months;
7. The following conditions must be met in terms of the time of the first administration of the investigational product: at least 28 days from the previous major surgery, medical device treatment, locoregional radiotherapy (except for palliative radiotherapy for bone lesions), cytotoxic chemotherapy, immunotherapy, or biological product therapy; at least 14 days from the previous small molecular targeted therapy; at least 14 days from the previous hormone therapy, administration of the traditional Chinese medicine for anti-tumor indications, or minor surgery; and recovery of treatment-induced AEs to grade ≤ 1 (CTCAE v5.0, except for alopecia);
8. Subjects who agree to provide archived tumor tissue specimens that meet the testing requirements (either from the most recent surgery or biopsy, preferably within 2 years) or agree to undergo a biopsy to collect tumor tissue for PD-L1 and DDX5 expression testing;
9. Adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration of the investigational product (no blood transfusions or treatment with granulocyte colony-stimulating factor within 14 days prior to the first administration)
10. For patients with hepatocellular carcinoma, Child-Pugh score must be A;
11. Male and female subjects with child-bearing potential must agree to use at least one highly effective contraception method during the study and within at least 6 months after the last administration of the investigational product; female subjects of childbearing age must have a negative pregnancy test within 7 days prior to enrollment.

Exclusion Criteria:

1. Patients who have history of other malignant tumors within 2 years prior to the first administration, except for cured cervical carcinoma in situ or cutaneous basal cell carcinoma;
2. Patients who previously have grade ≥ 3 irAEs in immunotherapy;
3. Patients who have history of (non-infectious) ILD requiring steroids, current ILD, or suspected ILD that cannot be ruled out by imaging at screening;
4. Subjects who are known to have severe anaphylaxis to protein preparations/ monoclonal antibodies or are allergic to any component in the formulation of the investigational product;
5. Patients who have active systemic infectious diseases requiring intravenous antibiotics within 2 weeks prior to the first administration of the investigational product;
6. Subjects who have any poorly-controlled cardiovascular and cerebrovascular clinical symptoms or diseases, including but not limited to: (1) NYHA Class II or greater heart failure or LVEF \< 50%; (2) unstable angina pectoris; (3) myocardial infarction or cerebrovascular accident within 6 months (except for lacunar infarction, slight cerebral ischemia, or transient ischemic attack); (4) poorly-controlled arrhythmia (including QTc intervals ≥ 450 ms for males and ≥ 470 ms for females) (QTc intervals are calculated by Fridericia's formula); (5) poorly-controlled hypertension (systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg after active treatment);
7. Patients who have been assessed as unsuitable for inclusion by the investigator, due to brain metastases, spinal cord compression, or cancerous meningitis with clinical symptoms, or uncontrolled brain or spinal cord metastases that have been evidenced; Note: Patients with asymptomatic or stable brain metastases, spinal cord compression, or cancerous meningitis as judged by the investigator are allowed to be enrolled.
8. Patients with known active or suspected autoimmune diseases. Those with autoimmune-related hypothyroidism and receiving thyroid hormone replacement therapy and those with type 1 diabetes mellitus controlled with insulin therapy are allowed to be enrolled;
9. Patients who have received systemic corticosteroids (prednisone \> 10 mg/day or an equivalent dose of a similar drug) or other immunosuppressive agents within 14 days prior to the first administration; Except: patients treated with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; those with short term use of corticosteroids for prophylaxis if a contrast agent is used;
10. Patients who have used potent CYP2D6/CYP3A inhibitors or inducers within 2 weeks prior to the first administration;
11. Patients with active tuberculosis;
12. Patients who have history of immunodeficiency, including HIV infection or other acquired or congenital immunodeficiencies, or history of organ transplantation;
13. Patients with active HBV or HCV infection or HBV/HCV co-infection;
14. Patients who have received live vaccines within 28 days prior to the first administration;
15. Pregnant or lactating women;
16. Subjects who are not suitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons as assessed by the investigator.

Primary outcomes:
measure: The Dose-Limiting Toxicity (DLT) of HLX43 within 21 days after the first Administration
timeFrame: From first dose to the end of Cycle 1 (each cycle is 3 weeks)
measure: The maximum tolerated dose (MTD) of HLX43
timeFrame: From first dose to the end of Cycle 1 (each cycle is 3 weeks)
Secondary outcomes:
measure: Objective response rate (ORR)
timeFrame: approximately up to 24 months
measure: Duration of response (DOR)
timeFrame: approximately up to 24 months.
measure: Progression-free survival (PFS)
timeFrame: approximately up to 24 months
measure: Overall survival (OS)
timeFrame: approximately up to 24 months
measure: Cmax
timeFrame: Up to 21 days after the first dose
measure: Tmax
timeFrame: Up to 21 days after the first dose
measure: T1/2
timeFrame: Up to 21 days after the first dose
measure: ADA (anti-drug antibody)
timeFrame: approximately up to 24 months
measure: Nab (neutralizing antibody)
timeFrame: approximately up to 24 months
measure: Number of subjects experiencing adverse events
timeFrame: Day 1 through 90 days after last dose.
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Hospital, Chinese Academy of Medical Sciences
state: Beijing
city: Changsha
country: China
facility: Xiangya Hospital Central South University
state: Hunan
Study officials:
affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
name: Jie Wang, Dr.
role: PRINCIPAL_INVESTIGATOR
References: